GNH USA

Europe — EMA

Nipruss (Sodium Nitroprusside Dihydrate)

GNH USA supplies Nipruss (Sodium nitroprusside), a vasodilator for hypertensive emergencies, acute heart failure and controlled hypotension.

Sodium Nitroprusside Dihydrate

Request sourcing

1
Pack/s

What is Sodium Nitroprusside Dihydrate?

Sodium nitroprusside, the active ingredient in Nipruss, is a vasodilator presented as an intravenous solution for intravenous use. It is employed in the rapid reduction of blood pressure and in the management of acute cardiac conditions.\n\nGNH India supplies Nipruss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

What is Sodium Nitroprusside Dihydrate used for?

Sodium nitroprusside is a rapid‑acting vasodilator used in the management of acute hypertensive and cardiac conditions.\n\nHypertensive emergencies: provides immediate, controlled reduction of severely elevated blood pressure.\nAcute heart failure: decreases preload and afterload to improve cardiac output.\nControlled hypotension during surgery: enables precise intra‑operative blood pressure control for reduced bleeding.

What are the side effects of Sodium Nitroprusside Dihydrate?

Sodium nitroprusside may cause a range of adverse reactions, from mild to life‑threatening.\n\nCommon Side Effects:\n- Headache\n- Nausea or vomiting\n- Flushing or warmth sensation\n- Dizziness or light‑headedness\n- Tachycardia\n- Transient increase in intracranial pressure\n\nSerious or Rare Side Effects:\n- Cyanide toxicity, presenting as metabolic acidosis or altered mental status\n- Thiocyanate accumulation leading to neurologic symptoms\n- Severe hypotension with organ hypoperfusion\n- Methemoglobinemia\n- Life‑threatening arrhythmias\n- Anaphylactic or severe allergic reactions

What precautions apply to Sodium Nitroprusside Dihydrate?

When using sodium nitroprusside, careful monitoring and specific precautions are essential.\n\nBlood pressure monitoring: continuous arterial pressure measurement is required to avoid overshoot hypotension.\nCardiac function assessment: monitor heart rate and rhythm, especially in patients with compromised myocardial function.\nCyanide risk management: limit infusion duration and consider antidote protocols in prolonged use.\nRenal or hepatic impairment: adjust therapy and monitor metabolite levels.\nPregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Sodium Nitroprusside Dihydrate interact with?

Sodium nitroprusside can interact with several drug classes, necessitating vigilance.\n\nMajor Interactions (Avoid):\n- Monoamine oxidase inhibitors (MAOIs): may cause profound hypotension.\n- Other potent vasodilators (e.g., nitroglycerin, hydralazine): additive blood pressure lowering effect.\n- Thiol‑containing agents (e.g., N‑acetylcysteine): increase cyanide production.\n\nModerate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: enhanced hypotensive response.\n- Diuretics: may potentiate volume depletion and hypotension.\n- Beta‑blockers: may mask tachycardia while allowing severe hypotension.\n- Calcium channel blockers: additive vasodilatory effect.\n- Renal‑impairing drugs: may affect clearance of cyanide metabolites.

Frequently asked questions

What is Nipruss used for?+
Nipruss contains sodium nitroprusside, an intravenous vasodilator employed in hypertensive emergencies, acute heart failure, and to produce controlled hypotension during surgical procedures. It works by rapidly lowering blood pressure, allowing clinicians to manage severe hypertension or facilitate a bloodless surgical field.
How does sodium nitroprusside work?+
Sodium nitroprusside releases nitric oxide when it enters the bloodstream. The nitric oxide activates guanylate cyclase, increasing cyclic GMP levels in vascular smooth muscle. Elevated cyclic GMP causes smooth‑muscle relaxation, leading to dilation of arteries and veins, which reduces both preload and afterload and rapidly lowers systemic blood pressure.
What is the usual dose of Nipruss?+
The dosing of Nipruss is individualized and must be determined by the prescribing clinician. Typically, the infusion is started at a low rate and titrated based on continuous blood pressure monitoring to achieve the desired therapeutic effect while avoiding excessive hypotension.
Is Nipruss safe in pregnancy or breastfeeding?+
Safety data for sodium nitroprusside in pregnancy and lactation are limited. It should be used only if the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with obstetric specialists.
How do I order Nipruss from GNH USA?+
To order Nipruss, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does Nipruss compare with other IV antihypertensives?+
Compared with agents such as nitroglycerin or nicardipine, sodium nitroprusside offers a more rapid onset and a balanced arterial‑venous dilation, allowing precise control of both preload and afterload. However, it requires vigilant monitoring for cyanide toxicity, a concern less prominent with many alternative IV antihypertensives.
What are the storage and handling requirements for Nipruss?+
Nipruss should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use, and any unused portion should be discarded according to local regulations after the recommended shelf‑life.
How is Nipruss administered?+
Nipruss is given as an intravenous infusion. The solution is diluted in a compatible carrier (often normal saline) and administered through a calibrated infusion pump. Continuous arterial blood pressure monitoring is essential, and the infusion rate is adjusted by the clinician to achieve the target hemodynamic response.
What are the most serious risks associated with Nipruss?+
The most critical risks include cyanide toxicity, which can manifest as metabolic acidosis, altered mental status, or seizures, and severe hypotension leading to organ hypoperfusion. Prompt recognition, regular laboratory monitoring, and availability of cyanide antidotes are vital to mitigate these hazards.
Who should not use Nipruss?+
Nipruss is contraindicated in patients with known hypersensitivity to sodium nitroprusside or its excipients, those with severe anemia, vitamin B12 deficiency, or significant renal or hepatic impairment that could impair cyanide clearance. It should also be avoided in patients with uncontrolled sepsis or shock where rapid vasodilation could worsen perfusion.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Sodium Nitroprusside Dihydrate
Route
Intravenous Use
Manufacturer
Oresund Pharma Aps
Origin
EU

Related products

Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Altamedics Gmbh
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Altamedics Gmbh
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Oresund Pharma Aps
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Oresund Pharma Aps
EU